G00002

162162

ABSTRACT

FUSION PROTEIN HAVING ENHANCED *IN VIVO* ACTIVITY OF ERYTHROPOIETIN

The present invention relates to a fusion protein having enhanced *in vivo* activity of erythropoietin wherein a carboxy terminal peptide fragment of thrombopoietin is fused with the carboxy terminal of human erythropoietin. This fusion protein has highly enhanced *in vivo* half-life due to increased carbohydrate content without loss of the inherent activity of erythropoietin, and does not cause any antigenicity when applied to the human body.

(Please note that Figure 3 should accompany the abstract when published)